<DOC>
	<DOCNO>NCT01791244</DOCNO>
	<brief_summary>This randomize , comparative , multicenter study assess impact patient support program ( MinSupport Plus ) health relate quality life ( HRQoL ) adherence subject relapsing-remitting multiple sclerosis administer Rebif® RebiSmart™ device .</brief_summary>
	<brief_title>A Phase 4 Study Assess Impact Patient Support Program Health Related Quality Life Adherence Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With RebiSmart™ Device</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Male female , age 18 old A diagnosis relapsingremitting multiple sclerosis accord revise McDonald Criteria ( 2010 ) Treatment Rebif® 22 44 mcg subcutaneously three time week accordance Summary product characteristic Rebif® administer RebiSmart™ device Provided sign informed consent form Has receive component , except technical support , MinSupport Plus prior study entry Has difficulty read and/or understand Swedish Has mental condition render subject unable understand nature , scope possible consequence study , and/or evidence uncooperative attitude No access computer Participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing-Remitting</keyword>
	<keyword>Rebif</keyword>
	<keyword>RebiSmart</keyword>
	<keyword>Patient support program</keyword>
</DOC>